

**FUTURE PLANS AND USE OF [REDACTED]**

**FUTURE PLANS**

See the section headed “Business — Our Strategies” for a detailed description of our future plans.

**USE OF [REDACTED]**

The table below sets forth the estimated net [REDACTED] of the [REDACTED] that we will receive after deduction of [REDACTED] fees and other estimated expenses payable by us in connection with the [REDACTED].

	Assuming the [REDACTED] is not exercised	Assuming the [REDACTED] is exercised in full
	<i>(in [REDACTED] of HK\$)</i>	
Assuming the maximum [REDACTED] of HK\$[REDACTED] per H Share . . . . .	[REDACTED]	[REDACTED]

We estimate that we will receive net [REDACTED] from the [REDACTED] of approximately HK\$[REDACTED] (after deducting the [REDACTED] fees and other estimated expenses payable by us in connection with the [REDACTED]), assuming the maximum [REDACTED] of HK\$[REDACTED] per H Share, and assuming the [REDACTED] is not exercised or HK\$[REDACTED], if the [REDACTED] is exercised in full. We intend to use the net [REDACTED] of the [REDACTED] for the following purposes:

- Approximately [REDACTED]% of the net [REDACTED], or HK\$[REDACTED] will be used for our global research and development efforts to strengthen the innovation of our products and intelli-digital solutions, with a strategic focus on advancing our high-end product lines and developing our intelli-digital healthcare ecosystem.
- o Approximately [REDACTED]% of the net [REDACTED], or HK\$[REDACTED] will be used to enhance the development and innovation of our products and solutions. This includes funding technological breakthroughs in our core business segments and product lines, developing intelli-digital integrated products and solutions, and accelerating the iterative upgrading of our products and solutions to meet evolving market demands.
- Approximately [REDACTED]% of the net [REDACTED], or HK\$[REDACTED] will be used for the IVD segment to further expand our R&D team and upgrade our product and within our existing fields while expanding into new areas. Concurrently, we will increase our investment to enhance the capabilities of our comprehensive intelli-digital testing laboratory solutions, driving underlying technological innovation centered around clinical needs:
  - We will continue to deepen our R&D investment in our established fields such as chemiluminescence immunoassay, biochemistry, and coagulation reagents, increasing the categories of reagent items. For instance, we expect to add at least 15 new chemiluminescence items annually over the next three years. By substituting and upgrading core raw materials and optimizing methodologies, we aim to further enhance reagent performance and precision. We will also actively expand into emerging tracks such as molecular diagnostics and mass spectrometry to launch innovative products. For example, we are currently developing a fully automated liquid chromatography-tandem mass

---

## FUTURE PLANS AND USE OF [REDACTED]

---

spectrometry integrated system, designed to achieve a fully automated testing process. We are also incorporating microbial mass spectrometry systems into our clinical mass spectrometry portfolio to promote the application of rapid microbial identification solutions. These R&D innovations will facilitate the widespread application of our IVD reagent products in major hospitals and regional testing centers both domestically and internationally, thereby consolidating and expanding our market share and further strengthening our international competitiveness in the IVD sector.

- We will increase our investment to enhance the capabilities of our comprehensive intelli-digital testing laboratory solutions. This includes elevating the level of laboratory automation and strengthening the integration of information systems to assist users in improving diagnostic efficiency while reducing manual intervention and errors. Through digital transformation, we can provide medical institutions with smarter and more efficient testing processes to meet growing clinical demands. Concurrently, leveraging our miInnoLab ecosystem, we will build an intelligent platform covering laboratory management and information systems. This will realize the automation of testing processes, intelligent result verification, and multidisciplinary collaboration, while promoting the application of AI in result verification and report interpretation, ultimately enhancing the efficiency of clinical-laboratory collaboration and the quality of diagnosis and treatment.
- We will persist in underlying technological innovation oriented towards clinical needs, with a particular focus on the construction of underlying methodological platforms. We will continue to build core technology platforms within the IVD field and leverage these platforms to drive full-chain innovation from raw materials to technologies and systems, thereby further improving product performance and testing accuracy to provide efficient and precise diagnostic solutions for clinical use. Furthermore, the continuous iteration and industrialization of these platforms will construct long-term technical barriers for us in the IVD field and provide powerful growth momentum for market expansion.

Our goal is to develop globally leading devices, reagents, and comprehensive intelli-digital laboratory solutions, accelerating our penetration in high-end markets and expanding into new product categories, driving rapid overall sales growth.

- Approximately [REDACTED]% of the net [REDACTED], or HK\$[REDACTED] will be used to drive technological innovation for our high-end medical devices. On one hand, we will continue to leverage the advantages of our multiple product lines. By combining different technology platforms and breaking through traditional product forms, we aim to achieve deep integration of software and hardware levels. We will drive the fusion and innovation of devices to provide more efficient and precise solutions tailored to specific clinical application scenarios. For example, we will develop a “full-scenario ultrasound + interventional ablation equipment” one-stop solution. By integrating four core stages: preoperative planning, intraoperative guidance, ablation treatment, and postoperative evaluation, we aim to construct a closed-loop ecosystem covering the entire diagnosis and treatment cycle. On the other hand, we will continue to develop ultra-high-end ultrasound systems to lead the expansion into the high-end ultrasound market both domestically and internationally, thereby enhancing our

---

## FUTURE PLANS AND USE OF [REDACTED]

---

international competitiveness. We will develop the Recho A20 ultra-high-end cardiac ultrasound device to further promote the application of image navigation technology in interventional treatments for structural heart diseases. Through this series of innovations, we will further consolidate and expand our market share in the global high-end medical device market.

- Approximately [REDACTED]% of the net [REDACTED], or HK\$[REDACTED] will be used for emerging business areas such as minimally invasive surgery, minimally invasive intervention and animal care:
  - In the field of minimally invasive surgery, while consolidating our core position in thoracic and abdominal surgery, we plan to further expand into niche segments such as ENT to drive the vertical extension of such business. We will gradually integrate AI and other advanced technologies into our products to promote the development of intelligent and standardized surgical procedures. Furthermore, by integrating our technological accumulation in laparoscopy, energy platforms, and surgical instruments, and leveraging the advantages of our vertically integrated supply chain, we will launch surgical robot products to realize technological breakthroughs and large-scale development for domestic surgical robots by synergizing with our existing intelli-digital businesses and further expanding applications in high-end surgical scenarios.
  - In the field of minimally invasive intervention, we will continue to consolidate our advantages in electrophysiology, coronary access, and peripheral vascular intervention. Simultaneously, we will actively expand into emerging interventional fields such as urology, gastroenterology, gynecology, and pulmonology to build a multidisciplinary, synergistic, and comprehensive interventional portfolio, realizing a strategic extension from vascular intervention to whole-body intervention. In addition to urology, gastroenterology, and gynecology interventions, we will establish a portfolio of high-value respiratory interventional consumables within the respiratory care field to further enhance our competitiveness in respiratory medicine and increase customer stickiness.
  - In the field of animal care, we will continue to advance our international strategic layout and perfect our animal IVD product matrix. We will strengthen innovation in the IVD field and drive technological and product innovation in areas such as patient monitoring and life support as well as medical imaging. Our goal is to form comprehensive animal care solutions across multiple product lines based on clinical needs.
- o Approximately [REDACTED]% of the net [REDACTED], or HK\$[REDACTED] will be used to expand our intelli-digital healthcare ecosystem and upgrade our holistic intelli-digital solutions.
  - Approximately [REDACTED]% of the net [REDACTED], or HK\$[REDACTED] will be used to further expand our intelli-digital healthcare ecosystem. This includes advancing our “Device + IT + AI” integration strategy, enhancing system capabilities through continuous clinical validation, and enabling efficient, high-quality clinical decision support systems. Our goal is to provide a breakthrough solution to the industry’s long-standing “impossible trinity” to drive sustainable, long-term

---

## FUTURE PLANS AND USE OF [REDACTED]

---

growth. We will also broaden the application scenarios of our intelli-digital solutions, strengthen connectivity and interoperability across devices and departments, unify underlying data within our integrated ecosystem, and promote adoption of our intelli-digital solutions across clinical workflows. We will continue to increase our R&D investment in clinical information systems, including CIS, PACS, and LIS, to perfect our product layout at the IT layer.

- Approximately [REDACTED]% of the net [REDACTED], or HK\$[REDACTED] will be used to further develop our LLMs for intelligent applications in various medical segments. We will focus our investment on the upgrade and optimization of our released vertical domain models, including critical care, perioperative care, medical engineering, obstetrics and gynecology, breast health, and testing, and develop deep intelligence agents. By integrating multi-modal data such as device data, medical assessments, and information systems, creating clinical intelligent assistants capable of continuous learning and evolution, and delivering analytical insights and decision support tailored to real-world clinical scenarios, we intend to refine customized precision medication, promote the standardization of high-quality care, and enhance hospital management efficiency, shaping a new paradigm in intelli-digital healthcare. Furthermore, we will deeply explore the intelligent application of vertical domain models in departments such as emergency medicine, general nursing, and medical imaging. We aim to deploy the power of intelli-digitalization across areas including assisted diagnosis and treatment, automated quality control, clinical case analysis and knowledge retrieval, teaching and scientific research, and talent development. Ultimately, we will form comprehensive intelli-digital solutions at both the departmental and cross-regional levels.
- o Approximately [REDACTED]% of the net [REDACTED], or HK\$[REDACTED] will be used to explore potential global acquisitions and partnerships, primarily focusing on strengthening our core business and supplementing specific product lines to enhance the comprehensive competitiveness of our existing operations and accelerate the development of high-growth businesses through mergers and acquisitions, so as to accelerate the growth of our core operations, extend and upgrade our recurring business, efficiently open up overseas consumables markets, and systematically enhancing technological advantages. As of the Latest Practicable Date, we have not identified any specific investment or acquisition targets, nor have we entered into any formal investment or acquisition agreements.
- Approximately [REDACTED]% of the net [REDACTED], or HK\$[REDACTED] will be used to further enhance our global sales network and supply chain capabilities.
  - o Approximately [REDACTED]% of the net [REDACTED], or HK\$[REDACTED] will be used to expand and refine our global marketing and distribution channels. This includes investment in localizing our sales and service teams, expanding our global sales network, and deepening our channel development. In particular:
    - Approximately [REDACTED]% of the [REDACTED], or HK\$[REDACTED] will be used for sales network development in emerging markets such as Latin America, Asia-Pacific, and the Middle and East Africa. We will establish localized sales teams with a core focus on IVD products to further enhance our service capabilities for premium customers. We will also increase efforts to optimize our distribution network and explore cooperation opportunities. By refining our market layout and strengthening localized services, we aim to further increase our penetration in emerging markets and

---

## FUTURE PLANS AND USE OF [REDACTED]

---

drive in-depth market development. We will work closely with local medical institutions to help clients improve their diagnostic and treatment capabilities and efficiency, thereby promoting the improvement of overall medical standards.

- Approximately [REDACTED]% of the [REDACTED], or HK\$[REDACTED] will be used for sales network development in mature markets. We will continue to optimize and expand our localized sales and service networks, further reach premium customer segments, strengthen brand influence, and drive deep penetration in mature markets. By optimizing our global high-end market layout, we aim to achieve greater breakthroughs in public markets and private high-end customer segments internationally, laying a more solid foundation for future market expansion and brand building.

In terms of products, we will continuously optimize the allocation of marketing resources. At the current stage, we will continue to prioritize the IVD) products as the core of our overseas market promotion, consolidating and expanding our leading advantage in this area. As emerging business product lines accelerate their launch, we will also gradually increase our global market presence and channel layout for businesses such as minimally invasive surgery and minimally invasive intervention. We will enhance the professional sales capabilities and clinical support abilities of our overseas consumables team through internal training and external recruitment to ensure better support for our overseas promotion and sales volume ramp-up in emerging businesses. Concurrently, we will open up new sales channels and optimize existing ones to deepen our market presence, ensuring that our emerging businesses can cover a broader market.

- o Approximately [REDACTED]% of the net [REDACTED], or HK\$[REDACTED] will be used to strengthen brand building and marketing initiatives. We intend to deepen our collaborations with leading hospitals and key opinion leaders to continuously elevate our brand influence and recognition in both developed and emerging markets worldwide. We plan to center our efforts around research-oriented hospitals and high-level clinical institutions in key regions to conduct joint scientific research, clinical studies, and multi-center project collaborations. By co-establishing demonstration departments, demonstration hospitals, and benchmark solutions, we aim to enhance our brand influence and recognition in professional fields domestically and internationally. Simultaneously, we will establish long-term mechanisms for talent development with research-oriented hospitals. With core target groups including ultrasound physicians and laboratory physicians, we will conduct systematic training, academic exchanges, and advanced courses. These initiatives will support the professional growth of young doctors and promote the deep integration of clinical practice with our innovative products and solutions, further consolidating our brand position in relevant niche segments.
- o Approximately [REDACTED]% of the net [REDACTED], or HK\$[REDACTED] will be used to invest in our supply chain and localization platforms to enhance our cross-regional supply resilience and delivery efficiency. In accordance with our overall plan to establish production capabilities in 14 countries by the end of 2026, we will gradually increase global production capacity. We will build production and warehousing platforms in regions including Europe, Middle and East Africa, Asia-Pacific, and Latin America. These initiatives aim to improve response speeds to regional customer demands and ensure the stability and timeliness of product supply. Furthermore, we will reserve localized production capabilities to support future additions of production bases and capacity expansion in more countries by building or acquiring overseas facilities for manufacturing, logistics, clinical support, and IT services to improve global production capacity, supply chain

---

## FUTURE PLANS AND USE OF [REDACTED]

---

resilience, and responsiveness. In addition, we will also enhance our after-sales service infrastructure to build a comprehensive global support system, investing in the refinement of distribution, after-sales service centers, and the strategic layout of warehousing and frontline service personnel to enhance customer service. In particular, we plan to accelerate the international expansion of our recurring business, such as our IVD products, and optimize our global supply chain layout, focusing on increasing production capacity and manufacturing and warehousing platforms construction of our IVD products, while expanding other business areas. By synergizing localized platforms with the scale advantages of intelligent manufacturing in China we aim to form a comprehensive global supply chain system.

- o Approximately [REDACTED]% of the net [REDACTED], or HK\$[REDACTED] will be used to upgrade our smart manufacturing systems. This will focus on advancing automation, digitalization, and intelligent production technologies to further improve manufacturing efficiency, consistency, and quality. We plan to conduct phased upgrades and renovations of core production bases with the Longhua Science and Technology Park as a model. We aim to establish an industrial IoT covering the entire manufacturing process to achieve intelligent production. This will ultimately lead to the construction of efficient, high-quality, and unmanned “light-out factories,” significantly improving capacity utilization and delivery capabilities. Simultaneously, we plan to build a global intelligent control platform and a digital operations system covering our major production bases. This will enable real-time monitoring and unified scheduling of production equipment, key processes, and supply chain links. By enhancing the visibility and controllability of multi-base and multi-category manufacturing activities, we will better support global order allocation and delivery requirements.
- Approximately [REDACTED]% of the net [REDACTED], or HK\$[REDACTED] will be used as working capital and for general corporate purposes.

The additional net [REDACTED] that we would receive if the [REDACTED] were exercised in full would be HK\$[REDACTED] assuming the maximum [REDACTED] of HK\$[REDACTED] per H Share. Additional net [REDACTED] received due to the exercise of any [REDACTED] will be used for the above purposes accordingly on a pro rata basis in the event that the [REDACTED] is exercised.

We will only place the net [REDACTED] of the [REDACTED] that are not immediately required for the above purposes into short-term interest-bearing accounts at licensed commercial banks and/or relevant authorized financial institutions as defined under the Securities and Futures Ordinance or applicable laws and regulations in relevant jurisdictions. In such event, we will comply with the appropriate disclosure requirements under the Listing Rules.